

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074986 A2

(51) International Patent Classification⁷: **C12Q 1/68**,
C07K 14/47, C12N 15/85, 5/10

(21) International Application Number: PCT/EP02/03013

(22) International Filing Date: 19 March 2002 (19.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/278,670 21 March 2001 (21.03.2001) US
60/282,463 10 April 2001 (10.04.2001) US

(71) Applicant (for all designated States except US): **EXON-HIT THERAPEUTICS S.A.** [FR/FR]; 26, rue Brunel, F-75017 Paris (FR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and
(75) Inventors/Applicants (for US only): **RESINK, Annelies** [NL/FR]; 48, rue Bobillot, F-75013 Paris (FR). **FUENTES, Nathalie** [FR/FR]; 4, rue Marc Sangnier, F-94270 Kremlin Bicetre (FR). **SCHWEIGHOFFER, Fabien** [FR/FR]; 38, avenue Paul Déroulède, F-94300 Vincennes (FR).

(74) Agents: **BECKER, Philippe** et al.; Becker et Associes, 10, rue de Milan, F-75009 Paris (FR).

(54) Title: AN EARLY PRE-SYMPTOMATIC PRION DIAGNOSTIC BLOOD TEST FOR ENCEPHALOPATHIES

(57) Abstract: This invention relates to compositions and methods of detecting enccephalopathies in a subject. This invention also relates to genetic markers, nucleic acid preparations or libraries, and kits for use in the implementation of said detection methods. The compositions and methods of this invention can also be used for the diagnosis, characterization, progression monitoring, etc. of enccephalopathies, including at early stages thereof, particularly Transmissible Spongiform Encephalopathies (TSE), including Bovine Spongiform Encephalopathies (BSE, "Mad Cow Disease").

WO 02/074986 A2

BEST AVAILABLE COPY

AN EARLY PRE-SYMPTOMATIC PRION DIAGNOSTIC BLOOD TEST FOR ENCEPHALOPATHIES

This invention relates to compositions and methods of detecting encephalopathies in a subject. This invention also relates to genetic markers, nucleic acid preparations or libraries, and kits for use in the implementation of said detection methods. The compositions and methods of this invention can also be used for the diagnosis, characterization, progression monitoring, etc. of encephalopathies, including at early stages thereof, particularly Transmissible Spongiform Encephalopathies (TSE), including Bovine Spongiform Encephalopathies (BSE, "Mad Cow disease").

Encephalopathies, more particularly Transmissible Spongiform Encephalopathies (TSEs) consist of a unique group of invariably fatal neurological disorders, which affect both human and animals and which are characterised by long pre-symptomatic incubation periods of months or years, and brain lesions associated with deposits of protease-resistant proteins. The nature of the infectious agent has not been definitively determined, although the predominant theory is that a previously unrecognised pathogenic agent called a prion, an abnormally folded protein, is responsible.

One of the most common form is Bovine Spongiform Encephalopathies (BSE), which affects cows and cause the "Mad Cow" disease. There is a new urgency in the efforts to determine the scale of the BSE epidemic and to safeguard public health. The EU (European Union) agreed last December to the systematic BSE diagnostic testing of all slaughtered cattle older than 30 months. Since BSE-incubation time in cattle is around five years, during which infection can probably be spread by lateral and vertical transmission, the development of an early pre-symptomatic test in living animals is of vital importance. Such a pre-clinical

diagnostic test will offer a means to reliably exclude infected animals from the human food chain. Furthermore, the infectious BSE agent can infect sheep and goats, including genotypes resistant to the sheep-specific TSE agent. This latter observation signals a need for pre-clinical testing program of BSE in sheep flocks
5 in order to prevent further human food contamination. So far, the only test available to identify the presence of BSE infection *prior to clinical manifestations of the disease* is a bioassay consisting of the injection of contaminated brain tissue into mice followed by the observation of disease development. Because this bioassay takes months to finish, it is an impractical tool for systematic testing.

10

As of November 2000, a total of 180,000 cows were found to be infected in United Kingdom and an additional 1,500 in Ireland, Portugal, Switzerland, Germany, Italy, Spain and France. Approximately 320,000 diagnostic tests have been performed to date using three products (from three companies) approved by
15 the EU. The average cost per test is \$23 (ranging from \$15 to \$30), not including the cost of obtaining the brain tissue sample. The EU is evaluating five other BSE tests, but like the three tests that are already approved, they cannot be performed until the animal is slaughtered. The EU has ordered that mandatory BSE testing begin in July 2001 for seven million slaughtered cows annually and it is expected
20 that a total of 10 million tests will be sold and administered over the coming year.

There is thus a need for new methods of detecting encephalopathies, particularly methods that can be performed on living animals, are rapid, and preferably, can detect the pathology at pre-symptomatic stage. It is the object of this invention to
25 provide such a pre-symptomatic blood test for encephalopathies, particularly for TSE, including BSE, in a mammal. The invention allows to readily test potentially every animal at risk, optionally multiple times, during the life of the animal. This invention also relates to genetic markers, nucleic acid preparations or libraries, and kits for use in the implementation of said detection methods.

30

Applicants have created a pre-symptomatic diagnostic test in easily accessible body fluids of living animals. Applicants have undertaken an extensive research and development program using an innovative approach to identify new markers for TSE. These and other aspects represent objects of the present application.

5

This invention thus relates to a method of detecting the presence of an encephalopathy in a subject, the method comprising (i) collecting or providing a biological sample containing nucleic acids from the subject, typically a fluid sample (e.g., blood, serum, saliva, urine, etc.), although other tissue or cell sample
10 may be used as well, and (ii) contacting said sample with at least a nucleic acid molecule comprising the sequence of all or part of a sequence selected from SEQ ID Nos 1-15 or a sequence complementary thereto, under conditions allowing hybridisation to occur, and (iii) determining the presence of such hybrids, the presence of hybrids indicating the presence of an encephalopathy in the subject.

15

This invention also relates to a method of determining or detecting subject (e.g., a mammal) at risk of developing an encephalopathy, the method comprising (i) collecting or providing a biological sample containing nucleic acids from the mammal, typically a fluid sample (e.g., blood, serum, saliva, urine, etc.), although
20 other tissue or cell sample may be used as well, and (ii) contacting said sample with at least a nucleic acid molecule comprising the sequence of all or part of a sequence selected from SEQ ID Nos 1-15 or a sequence complementary thereto, under conditions allowing hybridisation to occur, and (iii) determining the presence of such hybrids, the presence of hybrids indicating a risk of developing
25 an encephalopathy in the mammal.

The nucleic acid may be immobilized on a support, such as a chip, filter, membrane, glass slide, etc. The contacting step may comprise any combination of the above sequences and, typically, uses at least two, preferably at least 3.

30

In a first variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:1 or a functional equivalent thereof or a sequence complementary thereto.

5 SEQ ID NO: 1
NE206922 Preproelastase

10 CCCCAGAGAGGAGCCGAAGCTCACGATGCCATGCACCTGCCACTGGCCATTAGATGCCCCG
GCAATTCAGTGGTCCGCCAGAGTCCCCATTGCAGCTGGAGGTCACGCCGTCGCCACCAGC
GCACACCATGCTGGACTTCACAGAGCTTCCCCACCAGCTAGCGCTGGAGCAGGTGGCATA
GTCCACAACCAGCAGGCGGCCCTGCCTCAGGGTGTGAGGACTGTTCCCATTGGTCTGCAG
CAGGCCCCAGCCTGTGACATAGCAGACATAGTTTCTCGGGAGAATGGTGCCAGCGGGTGG
GAGGCAAGCTGTCTGGAT

15 In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:2 or a functional equivalent thereof or a sequence complementary thereto.

20 SEQ ID NO: 2
NE206230 Chymotrypsin-like protease

25 ATGGACCAGGGGTAGAACAACCTTGCTGCAGGCGAGCTGGTGTACATTGCCCACACCACT
GATTCGGCCCCAGCCAGTGGTGACACAGGTGAGCCCCGAAGGCAGTGCCTCGTTTGTGGA
AGCCAGGCAGACTGGTGAGACTTGTGCTGTGTACCGGGCTGGCGAGGCAAGCTTCAGGAG
AGTCAGGTCATTGTTTCATGGTGTGGCGTTCCAGTTAGGGTGGC

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:3 or a functional equivalent thereof or a sequence complementary thereto.

30 SEQ ID NO: 3
NE212490 Unknown

35 CGGTGGCAAGTCGGGTTCCAGGTCCATGAAGCCCCCGGGAGGAGAATCGAGCGATCTTTT
CGGAAGTCCAGAAGAAGGTATTTCTTCAAGCAAGCCTAATAGGATGGCATCTAATATTTT
CGGACCAACTGAAGAACCTAAAAACATACCCAAGAGGACAAATCCTCCAGGAGGCAAAGG
AAGTGGGATCTTTGATGAATCGACTCCTGTGCAAACTCGACAACGTTTGAATCCACCAGG
GGGGAAGACCAGTGACATATTTGGGTCCCCAGTCCT

40 In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:4 or a functional equivalent thereof or a sequence complementary thereto.

SEQ ID NO: 4

NE212911 Chymotrypsinogen

5 CAACAGACACAGTCTCAGAGAACTGGGCAGGAGTGGCCAGCTTCAGCAGGGTGATGTCAT
TACGCACGGTGAAGGAGTTGAACTTGGGGTTCTTAAAAACCTGAGCGATTTTCAGGACCT
GGACATTCTCTTCGTCGGAGCCCTGATCAAACTCTCCAGCTACCACCACATCGGTTGTCT
TGACCCCGCAGTGGGCAGCAGTGACCACCCAGTTTTCGCTGATGAGGGAGCCCCCGCAGA
10 AATGGAAGCCAGTTCTGTCTGCAGGGACACCTGCCAGGGCCAGGAGCCAGGGATAGCAT
CCT

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:5 or a functional equivalent thereof or a sequence complementary thereto.

15

SEQ ID NO: 5

NE211662 Amylase-2

GTCTTGGTGGTCCAATCCAGTCATTCTGATCTTTTCTTCTGGAAATTTCTATTCCAACG
20 GTAACTCGACATTACTCTTGTGAATCCATAAGGATGAGCCNTCATAAATCCGACAGCCAT
TTTATACATT

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:6 or a functional equivalent thereof or a sequence complementary thereto.

25

SEQ ID NO: 6

NE216391 Kinase substrate HASPP28

30 GGGTGGCCTCGAACTCAGAAATCCGCCTGCCTCTGCCTCCCGAGTGCTGGGATTAAAGGC
GTGGCCACCACGCCCCGGCTTTGCATGCTTTATTTCTTGTGGAATAACTGACACCCAAGTT
CTCCTTCAGAAGCTTCAGCCAAGCCCACCTTGAGGAACAAGACGAGGACACATGATGGGT
GAGACATGGCAGAGGTCCTGGCGGCACGGCCCAGTCCCCGGCATCTCTCCACAGGCC
35 AGCTACTTATTCAGGGACAGCGACTG

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:7 or a functional equivalent thereof or a sequence complementary thereto.

40 SEQ ID NO: 7

NE208331 Carboxyl ester lipase

CGTGGACGATGGCTAAGTACCGGTCTACAGCTATACAGGCCAGCAGCAGGCTGCTGCAGT
AGAAATTGATCTTGTGCAGAGCGATCACAGTTTTGCAGAGGAAGGTCCCTAGGACCCAAC

5 CCACAGAGCCCTCAGCCACTGCAAAAGGCAGGATGAAGACTAAGAGAAGGTCGGCTACTG
CGAGGTGGAACAGGAAGGTCTCGGTTGAGCTCCGCGTGTGCCGGTGCCTCTCCGGGATTG
CAGCACCAGGATGTTTCCCATCATACCCAGGAGGAAGATGAGGCTGTAGGCCAGGCATG
AATCCGCCTTAAGGACGTCAGTAAGGGTCCTCGACTGTAGAGCAGAAGTTCTGTCTGTA
GG

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:8 or a functional equivalent thereof or a sequence complementary thereto.

10

SEQ ID NO: 8
NE228092 Unknown

15 GGATGCATTTGAACTGATAAGGACTAGGTAGAAGGCTAGATGGAATGTTACGGC
CTAGGTATAACGTTAAGCCTAAGTAAGTCTTACGTGGCTAGCCTGCCATTTGCGCTGTT
ACTAGTATTATAAGGAACTTCCTTATGTGCAAGTTGATTGCATATTCTCTAAATTCTT
TGCTCTTGAACTGAGCACAACAGAGGTTAGTTAGAAGTCTCTGTATAGTTAGCCAAA
ATGAGCTTTGACCCAATCAGCCAATCAGCAGCACTTCTGCATATGTGTAAAGCTTGTATG
GTATCTGCTTTTATAAGCTG

20

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:9 or a functional equivalent thereof or a sequence complementary thereto.

25 SEQ ID NO: 9
NE230511 Unknown

30 GTGTCCAGGAGGGAAGTGGTATGATCTAATGAATCCTTTTACTAAGATGGGGATGTGATG
GTAGCACACAGCAGGGAAGAGGGACTTCGAATCTCAGGCCTCAGCTTAGAAGGGGAAGCA
CCTATTTCCTGCCCCCTTCTTTAAGACATCTCCCTTTTGCTGAGGCTTACCAGGGGGTA
GGGGAGCGCAGGGAAGGTCAAGGAGGTGTATCAAAAGTATC

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:10 or a functional equivalent thereof or a sequence complementary thereto.

35

SEQ ID NO: 10
NE230512 Unknown

40 AGACACTTTGATACACCTCCTTGACCTCCCTGCGCTCCCCTACCCCCTGGTAAGCCTCA
GCAAAAGGGAGATGTCTTAAAGAAAGGGGAGTGGAAATAGGTGCTTCCCCTCCTAAGCT
GGGGCCTGAGATTCTGAAGTCCCTCTTCCCTGCTGTGTGCTACCATCACATCCCCATCTTA
GTAAAAGGATTCATTAGATCATACCAGTTCCTCCTGGACACCC

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:11 or a functional equivalent thereof or a sequence complementary thereto.

5 SEQ ID NO: 11
NE230551 Unknown

TACCATGAGGGAGTGGCTGGATTAGGCCTAGGGAGGATGACTGTCCATGAGAGATGACAG
GTGTGGGCAGCTCTTCTAGGGGGTGTGGGCACTGGAGTAGCCTCAGGAGGCAGCGGCTCC
10 CCCGCTGTTGGTTCTGAGACTGGTGAGGCGGGACCAGCCCCGTTGTTCCAGTCTTCAT
GCCTGGTGGCACCCCTCA

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ
15 ID NO:12 or a functional equivalent thereof or a sequence complementary thereto.

SEQ ID NO: 12
NE230612 Unknown

20 GGGTAAAAGAGGGAAATGAAAAGGAGAGAGACAGTATCCAGCTCGGTAAACAGTTTCCCT
AAGTGTCTCCACCATGTGGAACACACAGGAGATTCATGGGAGTTGGGTAGAGAAGAGAA
GGGGGAAGGAGGAGACAGAGGCA

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ
25 ID NO:13 or a functional equivalent thereof or a sequence complementary thereto.

SEQ ID NO: 13
NE213890 G-protein beta2 subunit

30 CTGACCCAGATCACAGCCTGGGCTGGTACCCAGTGGGGCGAATTCAGATGAGTAACACGG
AGGACCCTCCGTGGACACCTGGCAAAAATCTATGCCATGCACTGGGGGACAGACTCAAGG
CTGCTGGTCAGCGCCTCCCAGGACGGAAAGCTCATCATTTGGGACAGCTCACCCTAACA
AGGTCCACGCCATCCCTCTGCGTTCTCTGGGTAATGACCTGTGCCTCGCCCCCTCAGG
35 GAACTTTGTGGCCTGTGGGGGTTTGGACAACATCTGCTCCATCTATAGTCTCAAGACCCG
AGAGGGCAAT

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ
40 ID NO:14 or a functional equivalent thereof or a sequence complementary thereto.

SEQ ID NO: 14

NE214232 Mitochondrion

5 TCGACCCCCGCCTGTTTACCAAAAACATCACCTCTAGCATTACAAGCTATTAGAGGCACT
GCCTGCCCAGTGACTAAAGTTTAACGGCCGCGGTATCCTGACCGTGCAAAGGTAGCATAA
TCACTTGTTCCCTTAATTAGGGACTAGCATGAACGGCTAAACGAGGGTCCAACGTCTCTT
ATCTTTAATCAGTGAAATTGACCTTTCAGTGAAGAGGCTGAAATATAATAATAAGACGAG
AAGACCCTATGGAGCTAAATTATATACTTATCTATTAATTTATAAACCTAATGGCCCAA
AACTAT

10

In a further variant, the contacting step above comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:15 or a functional equivalent thereof or a sequence complementary thereto.

15 SEQ ID NO: 15

NE211610 Exostoses multiple 2 (EXT2)

20 TGGCTGTGTCCCAGTTGTCATTGCAGACTCTTATATTCTGCCTTTCTCTGAAGTTCTGGA
CTGGAAGAGGGCATCTGTGGTCGTTCCAGAGGAAAAGATGTCAGATGTGTACAGCATCCT
GCAGAACATCCCACAGAGGCAGATTGAAGAGATGCAGAGACAGGCACGGTGGTTCTGGGA
GGCATACTTCCAGTCCATTAAAGCCATTGCCCTGGCCCCCTACAGATCATCAATGACAGG
ATCTATCCATATGCAGCCTCTCCTATGAAGAGTGGAATGACCCTCCTGCTGTGAAGTGGG
CTA

25 Preferably, for screening purposes, the biological sample is treated to render nucleic acids or polypeptides available for detection (e.g., for hybridization or antigen-antibody reaction). Treatment may include cell lysis, particularly using chemical, mechanical or physical means. Furthermore, the nucleic acids in the sample may be labeled prior to hybridization, for instance by conventional
30 radiolabels, fluorescent labels, enzymatic labels, chemoluminescent labels, etc. Hybridization can be performed under any conventional techniques and conditions, which are known to the skilled person and can be adjusted by the skilled person. In this regard, the hybridization can be carried out under high, intermediate or low stringency, depending on the desired level of sensitivity,
35 quantity of available material, etc. For instance conditions suitable for hybridization include a temperature of between about 62 and 67°C for 2 to 18 hours. Following hybridization, various washes may be performed to remove non-

hybridized molecules, typically in SSC buffers comprising SDS such as 0.1 to 10xSSC, 0.1%SDS.

In a typical experiment, the nucleic acids (or arrays or chips or filters) are
5 prehybridized in hybridization buffer (Rapid Hybrid Buffer, Amersham)
containing 100 µg/ml of salmon sperm DNA at 65°C for 30 min. The nucleic
acids from the sample are then applied to the filter (0.5×10^6 to 1×10^6 cpm/ml) at
65°C for 2 to 18 hours. Filters are washed in 5X SSC buffer, 0.1% SDS at 65°C
for 30 min then in 0.2X SSC buffer, 0.1% SDS. The hybridization profiles are
10 analyzed according to known techniques, for example by measuring the
radioactivity with an InstantImager (Packard Instruments). The hybridization
conditions may be adjusted by those skilled in the art according to conventional
techniques, particularly by decreasing the hybridization temperature and/or by
increasing the salt concentration of the hybridization buffer.

15

The invention also relates to various genetic markers of encephalopathies,
particularly TSEs. These markers have been identified from infected mammals
and can be detected in biological fluids, including blood, serum, saliva, urine, etc.,
i.e., with no need to perform tissue biopsies. The markers more specifically
20 represent qualitative genetic differences between healthy and affected mammals.
These markers have been prepared using the DATAS technology disclosed in
WO99/46403, incorporated therein by reference. DATAS identifies qualitative
differences between expressed genes and provides a systematic analysis of
alternative RNA splicing events between two conditions: either healthy/diseased,
25 untreated/treated or control/infected. Thus, DATAS leads to the identification of
functionally distinct RNA variants and thus also proteins, which play a role in
cellular equilibrium. The technique involves three different steps including tissue
collection, RNA isolation and construction of a database of events showing
qualitative differences. Identifying qualitative differences via DATAS clearly
30 holds a stronger interest for diagnostics than identifying sequences up or down

regulated through the use of classical genomic profiling approaches. DATAS-based qualitative differences represent *new sequence* fragments not present in previous expression profiles that can be selected for characterising a given pathophysiological situation.

5

Several different signatures (or genetic markers) that are present specifically in the blood from affected mammals have been isolated, as described in the examples. These genetic markers more precisely comprise all or part of any one of nucleic acid sequences SEQ ID Nos 1 to 15, or functional equivalents thereof.

10

This invention thus relates also to a nucleic acid molecule selected from the group of SEQ ID Nos 1-15 or a fragment thereof, a sequence complementary thereto or a functional equivalent thereof.

15 This invention also relates to a vector comprising a nucleic acid as described above, as well as to recombinant host cells comprising such a nucleic acid molecule or vector.

Another object of this invention lies in the use of a nucleic acid molecule
20 comprising the sequence of all or part of a sequence selected from SEQ ID Nos 1-15 or a sequence complementary thereto or a functional equivalent thereof, for the detection of a pathological event in a subject, more preferably of the presence of an encephalopathy.

25 Within the context of this invention, the term "functional equivalent of a sequence" designates any nucleic acid molecule that can hybridise with or detect said sequence or a complementary strand thereof, as well as any nucleic acid molecule that can hybridise with or detect a gene, RNA or genetic deregulation event (e.g., splicing, rearrangement, mutation, etc.) in a gene or RNA, that is
30 detected by said sequence. In other words, the present invention discloses the

identification of target genes and the methods or compositions of this invention include any nucleic acid sequence that can detect said gene or deregulation event in a sample. Such target genes include for instance a preproelastase gene or RNA comprising SEQ ID NO: 1, a chymotrypsin-like protease gene or RNA comprising
5 SEQ ID NO: 2, a chymotrypsinogen gene or RNA comprising SEQ ID NO: 4, an amylase-2 gene or RNA comprising SEQ ID NO: 5, a kinase substrate HASPP28 gene or RNA comprising SEQ ID NO: 6, a carboxyl ester lipase gene or RNA comprising SEQ ID NO: 7, a G-protein beta2 subunit gene or RNA comprising SEQ ID NO: 13, an exostoses multiple 2 gene or RNA comprising SEQ ID NO:
10 15, as well as any gene or RNA comprising SEQ ID NO: 3, 8-12 and 14. Functional equivalents may thus comprise a sequence that overlaps with one of the above sequences, or is specific for a distinct region in the gene or RNA, or for a distinct genetic alteration in the gene or RNA. Functional equivalents also include (i) corresponding nucleic acids from different species as well as (ii)
15 nucleic acid sequences having one or several sequence variation(s) such as mutation(s), substitution(s) addition(s) or deletion(s) of one or several bases, and retaining substantially the same specificity. Preferably, sequence variations do not affect more than 5% of the sequence.

20 The nucleic acid molecule may include all or part of the sequence disclosed, and may comprise additional sequence corresponding to synthetic sequence (e.g. cloning sites) or to flanking sequence in the target gene or RNA. The nucleic acid may be a DNA (e.g., cDNA, gDNA), RNA, oligonucleotide, PCR fragment, probe, etc. It may be single-stranded or double-stranded.

25

Within the context of the present invention, a "part" of the above nucleic acid sequences includes any fragment of said sequences comprising at least 5 consecutive bases, more preferably at least 7 consecutive bases, even more preferably at least 8 consecutive bases. Indeed, the fragment or part should be
30 sufficiently long to exhibit the selectivity of the entire sequence in a hybridisation

experiment under high stringency. Preferred part include at least 10 consecutive bases, typically at least 15 consecutive bases.

5 A sequence complementary to the above sequences designates any sequence having full complementarity therewith or only partial complementarity. Partial complementarity indicates that certain mismatches would be tolerated, as long as the nucleic acid retains a specificity in hybridisation experiments. For instance, a mismatch every 15 bases would not substantially alter the ability of a nucleic acid molecule to retain the hybridisation profile.

10

The invention preferably uses nucleic acid molecules of between about 10 and about 800 bases in length, specific for a gene as described above, for detecting encephalopathies in a sample.

15 The invention also includes vectors comprising a nucleic acid as defined above. The vector may be a plasmid, episome, chromosome, phage, virus, etc. The vector may comprise regulatory sequences, such as a promoter, origin of replication, selection gene, polyA sequence, secretion sequence, etc. Typical examples of plasmids include commercially available plasmids such as pBR, pUC, pcDNA, etc. Suitable examples of viruses include replication defective adenoviruses, 20 retroviruses, AAVs or herpes viruses.

Recombinant host cells comprising a nucleic acid or a vector as defined above include prokaryotic or eukaryotic cells, such as bacteria (e.g., *E. coli*), yeasts (e.g., 25 *Saccharomyces*, *Kluyveromyces*, etc.), plant cells, insect cells, mammalian cells, etc. Mammalian cells may be derived from various species, including rodents, bovines, monkey and humans. They may be primary cells or established cell lines. Such cells include, for instance, CHO, COS, 3T3, HeLa, etc.

The compositions and methods of this invention can be used for the diagnosis, characterization, progression monitoring, etc. of encephalopathies, including at early stages thereof, particularly Transmissible Spongiform Encephalopathies (TSE), including Bovine Spongiform Encephalopathies (BSE, "Mad Cow disease"). The invention is also suitable to detect vCJD in human beings.

The value of having a pre-symptomatic blood test is, inter alia :

- Identify the infected animal, and thus avert contact and subsequent infection with other members of the herd; current tests that rely on detection of the prion protein after slaughter can only detect the symptomatic stage of the disease;
- Keeps sick animals out of the slaughter-house; currently slaughter houses are full of infected animals, detected and undetected;
- Avoid complicated slaughter-house processing and tracking of animals, and avoid errors of mixing contaminated meat with meat approved for market;
- The blood test can be carried out a few days or a week before bringing animals to the slaughter house, while the current test creates a bottle-neck at the slaughter-house;
- Avoid the expense of brain tissue extraction and processing;
- Detect different stages of the disease – early and late forms;
- Animals found negative by the test can be re-tested to increase the opportunity to detect the disease, if present; and
- Prevent the social and economic impact of killing entire herds; farmers just do not want to see their herds killed without solid scientific evidence or demonstration that such extreme measures are necessary and warranted.

The disclosed diagnostic methods do not require knowledge, with certainty, of the infectious agent as it is based on identified markers of the presence of the disease and the progression of the disease from early to late stages.

The methods are advantageous since they can be used to test for early, pre-symptomatic BSE in animals incubating the disease, and since they work from a simple blood samples.

- 5 The invention describes genetic markers from circulating fluids, isolated from test animals that are suspected to participate in the disease progression, and thus to be encoded by genes critical for the progression of the disease, and further capable of distinguishing the early and late stages of the disease.
- 10 ▪ Studies were performed in several mammalian species:
- Reliable TSE-infected signatures have been detected in said species;
 - Genetic markers for the early, pre-symptomatic phase and symptomatic phases of the disease have been identified.
- 15 ▪ We have identified 5 signatures that are present in the blood of infected sheep;
- In 4 individual infected sheep studied, these 5 signatures are present in the blood and are up-regulated in comparison to 2 control sheep;
- 20 ▪ In mice, we have identified 7 signatures that are present in the spleen of infected mice and are up-regulated in comparison to control mice;
- The progression of the disease was studied over multiple timepoints:
 - signatures were followed over different timepoints from early stage to late stage of the disease;
 - 3 signatures were highly expressed (up-regulated) at 35 days (pre-symptomatic early stage) and the expression diminished
- 25 by 200 days (symptomatic late stage);

The new diagnostic test is thus based on a genome-wide analysis of differential expression of splice variants that occur between infected and uninfected individuals. By applying a unique gene profiling technology, DATAS

30 (Differential Analysis of Transcripts with Alternative Splicing), Applicants have

now identified genetic markers for TSE infection. From these data we selected those signatures of downstream events that are induced or inhibited by the TSE infectious agent. Based on the large number of events that have been screened and are being validated it is likely that this diagnostic test will have greater impact and value than the available prion-antibody-based analysis currently being used to address the epidemic.

The invention also relates to the polypeptides encoded by the above nucleic acid molecules, and their use for diagnostic or therapeutic purposes. More specifically, an object of this invention resides in a polypeptide, wherein said polypeptide has an amino acid sequence encoded by a nucleic acid molecule as defined above.

The invention also relates to antibodies (monoclonal or polyclonal) directed against said polypeptides, as well as fragments or derivatives of said antibodies (e.g. Fab, Fab'2, ScFv, humanized antibodies, etc.). Such antibodies may be produced according to conventional methods, including immunization of an animal and collection of serum (polyclonal) or spleen cells (to produce hybridomas by fusion with appropriate cell lines). Methods of producing polyclonal antibodies from various species are well known in the art. As an example, the antigen may be combined with an adjuvant (e.g., Freund's adjuvant) and administered to an animal, typically by sub-cutaneous injection. Repeated injections may be performed. Blood samples are collected and immunoglobulins or serum are separated. Methods of producing monoclonal antibodies from various species are also known in the art (Harlow et al., Antibodies: A laboratory Manual, CSH Press, 1988). Briefly, these methods comprise immunizing an animal with the antigen, followed by a recovery of spleen cells which are then fused with immortalized cells, such as myeloma cells. The resulting hybridomas produce the monoclonal antibodies and can be selected by limit dilutions to isolate individual clones.

Preferred antibodies of this invention are antibodies that specifically bind an epitope comprised in the polypeptides encoded by SEQ ID NOs: 1 to 15.

5 These antibodies can be used for therapeutic or diagnostic purposes. In particular, the test may be based on the detection of the above polypeptides or parts thereof in a biological sample, using said antibodies, optionally attached to a support.

In this regard, a further object of this invention resides in a method of detecting the presence or the risk of developing an encephalopathy in a subject, the method comprising (i) providing a biological sample containing proteins (or fragments thereof) from the subject, (ii) contacting said sample with at least an antibody as defined above, and (iii) determining the presence of antibody-antigen complexes, the presence of such complexes indicating the presence or the risk of developing an encephalopathy in the subject.

15

The present invention also concerns kits for the implementation of the aforementioned methods. The kits of the invention more generally comprise a nucleic acid molecule or antibody as defined above, or a nucleic acid array as defined above, or a nucleic acid preparation or library as defined above. The kits may further advantageously comprise control clones for calibration of the detected signals.

20

A specific object of this invention thus resides in a product comprising, immobilised on a support, at least one specific target molecule selected from a nucleic acid molecule, a vector, a polypeptide and an antibody as defined above. The support may be of various shapes, nature and origin, such as a filter, a membrane, a slide, a polymer, a glass, a plastic and a biomaterial.

25

The invention also encompasses nucleic acid arrays comprising at least one nucleic acid molecule or vector comprising the sequence of all or part of a sequence selected from SEQ ID Nos 1-15 or a sequence complementary thereto or a functional equivalent thereof. The array comprises preferably at least two
5 distinct nucleic acid molecules as defined above, more preferably at least 3, even more preferably at least 4. Typically, the array comprises at least 5, more specifically at least 8 of said molecules, or even all of them.

Nucleic acid arrays are preferably comprised of a nucleic acid molecule attached
10 to a support, such as a filter, membrane, slide, polymer, glass, plastic, biomaterial, etc. The support may be flat or not, solid or semi-solid. It includes beads, etc. Such DNA-chips or oligo-chips are also included in the instant invention. They can be prepared according to known techniques (see WO99/46403).

15 The invention also encompasses methods of selecting candidate drug compounds comprising contacting a test compound with a target selected from a nucleic acid molecule, a vector, a recombinant host cell, a polypeptide and an antibody as defined above, and assessing the ability of the test compound to bind to or to modulate the activity of said target in vitro or in vivo.

20

The invention also relates to the use of the above nucleic acid sequences as targets in screening assays to select candidate drug compounds. The screening assay comprises, for instance, contacting the target (nucleic acid or corresponding polypeptide or protein) with a test compound and assessing the ability of the test
25 compound to bind to or to modulate the activity of said target in vitro or in vivo.

Binding can be determined by any conventional technique, such as immunoassays, for instance, or binding assays (RIE, ELISA, SPA, FRET, etc.). Modulation of the activity can be assessed in various cellular assays or in acellular assays, using for
30 instance enzyme substrates, reporter genes, etc.

Other aspects of this invention will be described in the following examples, which should be regarded as illustrative and not limiting.

5 LEGEND TO THE FIGURES

Figure 1 : Identification of spleen markers associated with TSE infection

Figure 2 : Expression pattern of a genetic marker of TSE

Figure 3 : Identification of circulating markers using a Macro-array.

10

EXAMPLES

Example 1. TSE markers obtained in an experimentally infected mouse model

15

C57BL/6 mice were either intra-cerebrally or intra-peritoneally infected with brain homogenate containing the murine C506M3 strain derived from a natural case of sheep Scrapie. Control mice were inoculated with brain homogenate of healthy animals. At different time points before and at clinical appearance (i.e., pre-and
20 post-symptoms) diseased animals were sacrificed and total RNA of brain and spleen were prepared. Tissue samples were collected at 35, 70, 111, 148, 190 and 230 days after intra-peritoneal inoculation, whereas tissue collection was performed at 28, 63, 93, 121, 135 and 153 after intra-cerebral inoculation.

25 Brain samples were studied to identify genes involved in brain invasion and neurodegeneration.

Spleen samples were also evaluated since the PrpSc propagation is dependent on the immune system and is noticeably present in the spleen follicular dendritic
30 cells. The sequences identified from spleen samples are thus providing

information on the mechanisms involved in PrpSc propagation through the immune system. The signatures obtained from spleen represent the repertoire of qualitative differences that distinguish infected and non-infected situations that can arise in various cell types. Among these cells are the circulating blood cells whose gene expression can be altered by the presence of even low (currently undetectable) amounts of PrpSc. Since this PrpSc may be expressed either in the circulating cell with the altered profile, or in resident non-circulating cells interacting with the circulating cells, it can be envisioned that some of the signatures identified in spleen will be specifically detected in the blood cells of infected animals.

1.1. Identification of potential markers at different time points after infection

DATAS profiling assays were carried out between pooled RNAs derived from spleen or brain tissue from five infected and five control mice at different stages of the disease. A macro-array containing all DATAS fragments was constructed. TSE infected animals were profiled against control animals by differential hybridisation in order to identify TSE specific signatures. For each time point after infection the macro-array was hybridised with a minimum of two probes derived from control and infected tissue. Z-scores of each clone for each hybridisation were calculated. Statistical z-score analysis identified differentially expressed DATAS fragments with a probability of at least 95% by cross-comparison between the results obtained from the hybridisations with two control and two infected probes. Figure 1 below shows an example indicating that DATAS can identify spleen markers (outlined in red boxes) that are specifically associated with TSE infection.

Results of z-score analysis are indicated in the table below: numbers < -2 indicate a $> 95\%$ probability of down-regulation of clones, whereas $> +2$ reflect an up-regulation with a probability $> 95\%$.

5 *Summary table of identified markers*

Marker	Probe	Up/down regulation	Z-score (pre-clinical stage)
A	Spleen	up	4.10
B	Spleen	up	3.76
C	Spleen	up	3.52
D	Spleen	up	2.31
E	Spleen	up	3.2
F	Spleen	up	2.2
G	Spleen	up	2.7

1.2. *Kinetic studies of selected diagnostic candidates*

- 10 Candidates selected by differential hybridisation were further characterised in kinetic studies using quantitative PCR. Expression patterns of three potential candidates in spleen have been established in three infected mice and two control mice. Data were normalised to a reference gene, whose expression is not altered during disease progress. Northern blotting of individual spleen samples derived
- 15 from two control and infected mice at different times after infection confirmed the expression pattern previously estimated by quantitative PCR. Figure 2 shows the expression pattern of one candidate determined by quantitative PCR as well as Northern blotting, in each lane 20 μ g of total RNA was loaded.
- 20 The candidates validated so far were prioritised for analysis based on their cellular localisation. All encode proteins that can be processed and are normally secreted

by cells. It is reasonable to assume that their specific up regulation can be detected in blood at the level of RNA in circulating cells or at the level of proteins directly in blood.

5

Example 2. Diagnostic markers obtained in a naturally infected Romanov sheep flock

LVK sheep are either naturally infected by or resistant to Scrapie. The symptoms of Scrapie appear on infected animals after 12 months. The first year of life of these animals corresponding to the pre-symptomatic phase. Spleen tissue was obtained from these animals at the age of 6 and 9 months and total RNA of spleen samples were prepared. In addition, total RNA of blood was prepared from Scrapie infected sheep at preclinical and clinical phases.

15

DATAS profiling was performed on RNA derived from spleen and pre-clinical blood samples of infected and resistant/control sheep. The macro-array containing all the DATAS fragments isolated in the sheep model was hybridised with probes derived from blood samples collected from two control sheep, four infected sheep in pre-clinical and clinical phase of the disease. Differential expression was also determined in pooled spleen samples derived from four infected and four resistant sheep at 6 months old. A macro-array challenged with a blood probe is shown in figure 3, indicating that we can identify circulating markers.

25 In total, three candidates were isolated by hybridisation performed with probes derived from blood samples and two by hybridisation with spleen samples. Probing the mouse macro-array with individual sheep blood probes resulted in the identification of two additional candidates. The table below shows the results of the z-scores analysis: numbers < -2 indicate a $> 95\%$ probability of down-

regulation of clones, whereas numbers $> +2$ reflect an up-regulation with a probability $> 95\%$.

Summary table of identified markers hybridising sheep macro-array

Marker	Probe	Up/down regulation	Z-score Pre-clinical stage	Z-score Clinical stage
1	Blood	down	-1.9	-2.5
2	Blood	up	3.4	3.9
3	Blood	down	-2.1	-2.3
4	Spleen	down	-2.6	
5	Spleen	up	2.8	

5

Summary table of identified markers hybridising mouse macro-array

Marker	Probe	Up/down regulation	Z-score Pre-clinical stage	Z-score Clinical stage
6	Blood	down	-2.17	-1.7
7	Blood	down	-2.46	-2.55

For some genes a direct functional link could be established based on literature research. Irrespective of the outcome of the reverse Northern blotting, those potential markers are included in subsequent research.

Eight potential markers are currently under investigation in terms of their expression levels during TSE progress. Furthermore, their expression patterns in blood will be correlated to different polymorphisms of the prion protein known to be associated with the sensitivity of sheep to the Scrapie agent. ExonHit has access to blood samples of sheep with the ARR/ARR genotype, which are resistant to prion disease, with the VRQ/VRQ genotype, which is highly sensitive to Scrapie infection and with the ARR/VRQ genotype, which has an incidence disease of 5%. Furthermore, blood samples from a kinetic study in sheep

15

experimentally infected with the BSE agent are being collected for ExonHit in order to determine their inducibility by the BSE agent of the early-identified markers.

5

Example 3. Identification of circulating BSE markers at pre-symptomatic stages

Markers identified in the sheep and mouse model can be validated in BSE infected
10 cattle by quantitative PCR and Northern blotting. Macro-arrays containing DATAS fragments isolated in both the sheep and mouse model can be challenged with a panel of blood probes derived from BSE infected cattle at pre-clinical stages in order to identify new BSE specific signatures.

15 Concurrently with the analysis outlined above, further DATAS experiments using blood samples of BSE infected cattle at different pre-clinical stages in comparison to healthy animals can be performed to identify additional potential markers. The identified candidate markers will be further validated performing quantitative PCR, and added to the final diagnostic if necessary.

20

A typical diagnostic assay is based on the use of DNA chip, PCR detection or antibody detection.

CLAIMS

1. A method of detecting the presence or the risk of developing an encephalopathy in a subject, the method comprising (i) providing a biological sample containing
5 nucleic acids from the subject, (ii) contacting said sample with at least a nucleic acid molecule comprising the sequence of all or part of a sequence selected from SEQ ID Nos 1-15 or a sequence complementary thereto, under conditions allowing hybridisation to occur, and (iii) determining the presence of hybrids, the presence of such hybrids indicating the presence or the risk of developing an
10 encephalopathy in the subject.
2. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:1 or a functional equivalent thereof or a sequence complementary
15 thereto.
3. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:2 or a functional equivalent thereof or a sequence complementary
20 thereto.
4. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:3 or a functional equivalent thereof or a sequence complementary
25 thereto.
5. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:4 or a functional equivalent thereof or a sequence complementary
30 thereto.

6. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:5 or a functional equivalent thereof or a sequence complementary thereto.

7. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:6 or a functional equivalent thereof or a sequence complementary thereto.

8. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:7 or a functional equivalent thereof or a sequence complementary thereto.

9. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:8 or a functional equivalent thereof or a sequence complementary thereto.

10. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:9 or a functional equivalent thereof or a sequence complementary thereto.

11. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:10 or a functional equivalent thereof or a sequence complementary thereto.

12. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:11 or a functional equivalent thereof or a sequence complementary thereto.

13. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:12 or a functional equivalent thereof or a sequence complementary thereto.

14. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:13 or a functional equivalent thereof or a sequence complementary thereto.

15. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:14 or a functional equivalent thereof or a sequence complementary thereto.

16. The method of claim 1, wherein the contacting step comprises contacting the sample with at least a nucleic acid molecule comprising the sequence of all or part of SEQ ID NO:15 or a functional equivalent thereof or a sequence complementary thereto.


17. The method of any one of claims 1 to 16, wherein the nucleic acid is immobilized on a support, such as a chip, filter, membrane or a glass slide.

18. The method of any one of claims 1 to 16, wherein the biological sample comprises blood, serum, saliva, urine, a tissue sample or a cell sample, preferably blood.
- 5 19. A nucleic acid molecule selected from the group of SEQ ID Nos 1-15 or a fragment thereof, a sequence complementary thereto or a functional equivalent thereof.
20. A vector comprising a nucleic acid of claim 19.
- 10 21. A recombinant host cell comprising at least one nucleic acid molecule of claim 19 or vector of claim 20.
22. A nucleic acid array comprising at least one nucleic acid molecule of claim 19 or vector of claim 20.
- 15 23. A polypeptide, wherein said polypeptide has an amino acid sequence encoded by a nucleic acid molecule of claim 19.
- 20 24. An antibody that binds a polypeptide of claim 23.
- 25 25. A product comprising, immobilised on a support, at least one specific target molecule selected from a nucleic acid molecule of claim 19, a vector of claim 20, a polypeptide of claim 23 and an antibody of claim 24.
26. The product of claim 25, wherein the support is selected from a filter, a membrane, a slide, a polymer, a glass, a plastic and a biomaterial.
27. The use of a nucleic acid molecule comprising the sequence of all or part of a sequence selected from SEQ ID Nos 1-15 or a sequence complementary thereto or
- 30


a functional equivalent thereof, for the detection of a pathological event in a subject, more preferably of the presence of an encephalopathy.

28. A method of selecting candidate drug compounds comprising contacting a test
5 compound with a target selected from a nucleic acid molecule of claim 19, a
vector of claim 20, a polypeptide of claim 23 and an antibody of claim 24, and
assessing the ability of the test compound to bind to or to modulate the activity of
said target in vitro or in vivo.
- 10 29. A method of detecting the presence or the risk of developing an
encephalopathy in a subject, the method comprising (i) providing a biological
sample containing proteins from the subject, (ii) contacting said sample with at
least an antibody of claim 24, and (iii) determining the presence of antibody-
antigen complexes, the presence of such complexes indicating the presence or the
15 risk of developing an encephalopathy in the subject.
30. The method of claim 1, wherein the subject is a mammal selected from a cow,
sheep or a goat.

1/3

**Figure 1**

2/3

**Figure 2**

3/3




Figure 3

SEQUENCE LISTING

<110> Exonhit Therapeutics SA

<120> An early pre-symptomatic prion diagnostic blood test
for encephalopathies

<130> B0072WO

<140>

<141>

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 318

<212> DNA

<213> mammalian

<400> 1

```

ccccagagag gagccgaagc tcacgatgcc atgcacctgc cactggccat tagatgcccg 60
gcaattcagt ggtccgccag agtccccatt gcagctggag gtcacgccgt cgccaccagc 120
gcacaccatg ctggacttca cagagcttcc ccaccagcta gcgctggagc aggtggcata 180
gtccacaacc agcaggcggc cctgcctcag ggtgtcagga ctgttcccat tggctctgcag 240
caggccccag cctgtgacat agcagacata gtttctcggg agaatgggtgc cagcgggtgg 300
gaggcaagct gtctggat                                     318

```

<210> 2

<211> 224

<212> DNA

<213> mammalian

<400> 2

```

atggaccagg ggtagaacaa cttgctgcag gcgagctggg gtcacattgc ccacaccact 60
gattcggccc cagccagtgg tgacacaggt gagccccgaa ggcagtgcct cgtttgtgga 120
agccaggcag actggtgaga cttgtgctgt gtaccgggct ggcgaggcaa gcttcaggag 180
agtcaggtca ttgttcatgg tgttggcgtt ccagttaggg tggc                                     224

```

<210> 3

<211> 276

<212> DNA

<213> mammalian

<400> 3

```

cgggtggcaag tcgggtttcca ggtccatgaa gcccccgga ggagaatcga gcgatctttt 60
cggaagtcca gaagaaggta tttcttcaag caagcctaag aggatggcat ctaatatattt 120
cggaccaact gaagaacctt aaaacatacc caagaggaca aatcctccag gaggcaaagg 180
aagtgggatc ttgatgaat cgactcctgt gcaaaactcga caacgtttga atccaccagg 240
ggggaagacc agtgacatat ttgggtcccc agtcct 276

```

<210> 4

<211> 303

<212> DNA

<213> mammalian

<400> 4

```

caacagacac agtctcagag aactgggcag gagtggccag cttcagcagg gtgatgtcat 60
tacgcacggt gaaggagttg aacttgggt tcttaaaaac ctgagcgatt ttcaggacct 120
ggacattctc ttcgtcggag ccctgatcaa actctccagc taccaccaca tcggttgtct 180
tgaccccgca gtgggcagca gtgaccaccc agttttcgct gatgaggagg ccccgagca 240
aatggaagcc agttctgtcc tgcagggaca cctgccaggg ccaggagcca gggatagcat 300
cct 303

```

<210> 5

<211> 130

<212> DNA

<213> mammalian

<400> 5

```

gtcttggtgg tccaatccag tcattctgat cttttccttc tggaaatttc tattccaacg 60
gtaactcgac attactcttg tgaatccata aggatgagcc ntcataaatc cgacagccat 120
tttatacatt 130

```

<210> 6

<211> 266

<212> DNA

<213> mammalian

<400> 6

```

gggtggcctc gaactcagaa atccgcctgc ctctgcctcc cgagtgctgg gattaaaggc 60
gtggccacca cgcccggett tgcattgctt atttcttggt gaataactga caccaagtt 120
ctccttcaga agcttcagcc aagcccacct tgaggaacaa gacgaggaca catgatgggt 180
gagacatggc agaggtcctg gcggcacggc ccagttcccc ggcattctct cccacaggcc 240
agctacttat tcagggacag cgactg 266

```

<210> 7

<211> 362

<212> DNA

<213> mammalian

<400> 7

```

cgtggacgat ggctaagtac cgggtctacag ctatacaggc cagcagcagg ctgctgcagt 60
agaaattgat cttgtgcaga ggcatacacag ttttgacagag gaaggcccct aggacccaac 120
ccacagagcc ctcagccact gcaaaaggca ggatgaagac taagagaagg tcggctactg 180
cgagggtgaa caggaaggtc tcggttgagc tccgcgtgtg ccggtgcctc tccgggattc 240
cagcaccagg atgtttccca tcatacccag gaggaagatg aggctgtagg cccaggcatg 300
aatccgcctt aaggacgtca gtaagggtcc ctcgactgta gagcagaagt tctgtctgta 360
gg

```

<210> 8

<211> 320

<212> DNA

<213> mammalian

<400> 8

```

ggatgcattt gaactgataa ggactaggta gaactgaagg gctagatgga atgttacggc 60
ctaggataaa cgttaagcct aagtaactct tacgtggcta gcctgccatt ttgcgctgtt 120
actagtatta taaggaaact tccttatgtg caagttgatt gcatattctc ttaaattctt 180
tgctcttgga aactgagcac aacagagggt agttagaact gctctgtata gttagccaaa 240
atgagctttg acccaatcag ccaatcagca gcacttctgc atatgtgtaa agcttgtatg 300
gtatctgctt ttataagctg

```

<210> 9

<211> 220

<212> DNA

<213> mammalian

<400> 9

```

gtgtccagga gggaaactgg atgatctaataaat gaatcctttt actaagatgg ggatgtgatg 60
gtagcacaca gcagggaaga gggacttcga atctcaggcc tcagcttaga aggggaagca 120
cctattttcca ctgccccttc tttaagacat ctcccttttg ctgaggctta ccagggggta 180
ggggagcgca ggggaaggta aggaggtgta tcaaagtatc

```

<210> 10

<211> 224

<212> DNA

<213> mammalian

<400> 10

```

agacactttg atacacctcc ttgaccttcc ctgcgctccc ctaccccttg gtaagcctca 60
gcaaaaggga gatgtcttaa agaaaggggc agtggaataa ggtgcttccc ctccaaagct 120
ggggcctgag attcgaagtc cctcttccct gctgtgtgct accatcacat ccccatctta 180
gtaaaaggat tcattagatc ataccagttc cctcctggac accc

```

<210> 11
 <211> 197
 <212> DNA
 <213> mammalian

<400> 11
 taccatgagg gagtggctgg attaggccta gggaggatga ctgtccatga gagatgacag 60
 gtgtgggcag ctcttctagg ggggtgtgggc actggagtag cctcaggagg cagcggctcc 120
 cccgctgttg gttctgagac tggtgaggcg ggaccagccc cgttgtttcc agttcttcat 180
 gcctgggtggc accctca 197

<210> 12
 <211> 143
 <212> DNA
 <213> mammalian

<400> 12
 gggtaaaaga gggaaatgaa aaggagagag acagtatcca gctcggtaaa cagtttccct 60
 aagtgttctc caccatgtgg aacacacagg agattcatgg gagttgggta gagaagagaa 120
 gggggaagga ggagacagag gca 143

<210> 13
 <211> 310
 <212> DNA
 <213> mammalian

<400> 13
 ctgacccaga tcacagcctg ggctggtacc cagtggggcg aattcagatg agtaacacgg 60
 aggacctcc gtggacacct ggcaaaaatc tatgcatgc actgggggac agactcaagg 120
 ctgctggtca ggcctccca ggacggaaag ctcattatc gggacagctc accactaaca 180
 aggtccacgc catccctctg cgttcctcct gggtaatgac ctgtgcctcg cccctcagg 240
 gaactttgtg gcctgtgggg gtttgacaa catctgctcc atctatagtc tcaagaccgg 300
 agagggaat 310

<210> 14
 <211> 306
 <212> DNA
 <213> mammalian

<400> 14
 tcgacccccg cctgtttacc aaaaacatca cctctagcat tacaagctat tagaggcact 60
 gcctgcccag tgactaaagt ttaacggccg cggtatcctg accgtgcaaa ggtagcataa 120
 tcacttggtc cttaattagg gactagcatg aacggctaaa cgagggtcca actgtctctt 180

atctttaatc agtgaaattg acctttcagt gaagaggctg aaatataata ataagacgag 240
aagaccctat ggagctaaat tatataactt atctattaat ttataaacct aatggcccaa 300
aactat 306

<210> 15

<211> 303

<212> DNA

<213> mammalian

<400> 15

tggtgtgtc ccagttgtca ttgcagactc ttatatcttg cttttctctg aagttctgga 60
ctggaagagg gcatctgtgg tggttccaga ggaaaagatg tcagatgtgt acagcatcct 120
gcagaacatc ccacagaggc agattgaaga gatgcagaga caggcacggt ggttctggga 180
ggcatacttc cagtccatta aagccattgc cctggccccc tacagatcat caatgacagg 240
atctatccat atgcagcctc tcctatgaag agtggaatga ccctcctgct gtgaagtggg 300
cta 303

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074986 A3

(51) International Patent Classification⁷: **C12Q 1/68**,
C07K 14/47, C12N 15/85, 5/10, G01N 33/50, 33/68

(21) International Application Number: PCT/EP02/03013

(22) International Filing Date: 19 March 2002 (19.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/278,670 21 March 2001 (21.03.2001) US
60/282,463 10 April 2001 (10.04.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **EXON-HIT THERAPEUTICS S.A.** [FR/FR]; 26, rue Brunel, F-75017 Paris (FR).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) *for US only*

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **RESINK, Annelies** [NL/FR]; 48, rue Bobillot, F-75013 Paris (FR). **FUENTES, Nathalie** [FR/FR]; 4, rue Marc Sangnier, F-94270 Kremlin Bicetre (FR). **SCHWEIGHOFFER, Fabien** [FR/FR]; 38, avenue Paul Déroulède, F-94300 Vincennes (FR).

(88) Date of publication of the international search report:
4 December 2003

(74) Agents: **BECKER, Philippe** et al.; Becker et Associés, 35 rue des Mathurins, F-75008 Paris (FR).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/074986 A3

(54) Title: AN EARLY PRE-SYMPTOMATIC PRION DIAGNOSTIC BLOOD TEST FOR ENCEPHALOPATHIES

(57) Abstract: This invention relates to compositions and methods of detecting encephalopathies in a subject. This invention also relates to genetic markers, nucleic acid preparations or libraries, and kits for use in the implementation of said detection methods. The compositions and methods of this invention can also be used for the diagnosis, characterization, progression monitoring, etc. of encephalopathies, including at early stages thereof, particularly Transmissible Spongiform Encephalopathies (TSE), including Bovine Spongiform Encephalopathies (BSE, "Mad Cow Disease").

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/03013

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 C07K14/47 C12N15/85 C12N5/10 G01N33/50
G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE 199 18 141 A (BOEHRINGER INGELHEIM VETMED) 26 October 2000 (2000-10-26) page 2, line 67 - page 4, line 41; claims 1-38 -----	1
A	DE 199 17 838 A (BUNDESREPUBLIK DEUTSCHLAND LET) 13 July 2000 (2000-07-13) page 2, line 57 - page 4, line 27 -----	1
A	US 6 033 858 A (BASTIAN FRANK O) 7 March 2000 (2000-03-07) the whole document -----	1
A	US 5 618 673 A (NARANG HARASH K) 8 April 1997 (1997-04-08) column 2, line 45 - line 67; claims 1-58; example 2 ----- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

31 July 2003

Date of mailing of the international search report

27.10.2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Osborne, H.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/03013

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 04237 A (PREDDIE ENRIQUE R ;BERGMANN JOHANNA E (DE)) 28 January 1999 (1999-01-28) the whole document -----	1
A	WO 99 47932 A (EBRINGER ALAN ;KING S COLLEGE UNIVERSITY OF L (GB)) 23 September 1999 (1999-09-23) page 2, paragraph 2; claim 7 -----	1
A	WO 98 26293 A (NEUROMARK ;HARRINGTON MICHAEL G (US)) 18 June 1998 (1998-06-18) page 1, line 13 - page 2, line 16 -----	1
A	OTTO M ET AL: "ELEVATED LEVELS OF TAU-PROTEIN IN CEREBROSPINAL FLUID OF PATIENTS WITH CREUTZFELDT-JAKOB DISEASE" NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 225, no. 3, 11 April 1997 (1997-04-11), pages 210-212, XP001003009 ISSN: 0304-3940 Abstract page 212 -----	1
A	HOCHSTRASSER D F ET AL: "Elevation of apolipoprotein E in the CSF of cattle affected by BSE" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 416, no. 2, 20 October 1997 (1997-10-20), pages 161-163, XP004261330 ISSN: 0014-5793 Introduction and Discussion -----	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/03013

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-30, all partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-30, all partially

A method for detecting the presence or the risk of developing an encephalopathy in a biological substance of a subject based on determining the presence of a nucleic acid sequence complementary to SEQ ID No 1 or to the polypeptide encoded by SEQ ID No 1; and SEQ ID NO 1 derived products.

2. claims: 1-30, all partially

A method for detecting the presence or the risk of developing an encephalopathy in a biological substance of a subject based on determining the presence of a nucleic acid sequence complementary to SEQ ID No 2 or to the polypeptide encoded by SEQ ID No 2; and SEQ ID NO 2 derived products.

3. claims: 1-30, all partially

A method for detecting the presence or the risk of developing an encephalopathy in a biological substance of a subject based on determining the presence of a nucleic acid sequence complementary to SEQ ID No 3 or to the polypeptide encoded by SEQ ID No 3; and SEQ ID NO 3 derived products.

4. claims: 1-30, all partially

Inventions 4-15.

A method for detecting the presence or the risk of developing an encephalopathy in a biological substance of a subject based on determining the presence of a nucleic acid sequence complementary to SEQ ID No X or to the polypeptide encoded by SEQ ID No X; and SEQ ID NO X derived products, wherein X is a sequence selected from SEQ ID No 4-15.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/03013

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19918141	A	26-10-2000	DE 19918141 A1	26-10-2000
			AU 4297400 A	10-11-2000
			BG 106021 A	28-06-2002
			BR 0009843 A	13-02-2002
			CA 2367696 A1	02-11-2000
			CN 1347501 T	01-05-2002
			CZ 20013771 A3	13-03-2002
			EE 200100547 A	17-02-2003
			WO 0065357 A1	02-11-2000
			EP 1093585 A1	25-04-2001
			HU 0200777 A2	29-06-2002
			JP 2002543389 T	17-12-2002
			NO 20015094 A	17-12-2001
			PL 350985 A1	24-02-2003
			SK 15032001 A3	05-02-2002
			TR 200103011 T2	21-02-2002
			US 2003129667 A1	10-07-2003
			US 2003064424 A1	03-04-2003
DE 19917838	A	13-07-2000	DE 19917838 A1	13-07-2000
US 6033858	A	07-03-2000	NONE	
US 5618673	A	08-04-1997	AU 2379692 A	16-03-1993
			CA 2115829 A1	04-03-1993
			DE 69222948 D1	04-12-1997
			DE 69222948 T2	12-03-1998
			EP 0613501 A1	07-09-1994
			WO 9304198 A1	04-03-1993
			GB 2258867 A ,B	24-02-1993
			JP 6510185 T	17-11-1994
			NZ 243922 A	26-10-1994
WO 9904237	A	28-01-1999	CA 2206774 A1	16-12-1998
			AU 8972998 A	10-02-1999
			WO 9904237 A2	28-01-1999
			EP 1062517 A2	27-12-2000
			JP 2001501314 T	30-01-2001
			US 2002155552 A1	24-10-2002
WO 9947932	A	23-09-1999	AU 750634 B2	25-07-2002
			AU 2948799 A	11-10-1999
			CA 2323597 A1	23-09-1999
			EP 1064555 A2	03-01-2001
			WO 9947932 A2	23-09-1999
WO 9826293	A	18-06-1998	AU 5601298 A	03-07-1998
			WO 9826293 A1	18-06-1998

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.